Gestational trophoblastic neoplasia: management and outcomes with EMACO regimen
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252748Keywords:
EMACO, GTN, High risk, Low-risk relapse, Fertility preservationAbstract
Gestational trophoblastic neoplasia (GTN) is a rare and malignant condition arising from the maternal placental tissue. It is a highly chemo sensitive tumor, EMACO (etoposide/methotrexate/dactinomycin alternating with cyclophosphamide and vincristine) is the most common multiagent chemotherapy used for patients with high risk. An audit was conducted for patients with gestational trophoblastic disease (GTN) receiving EMACO regimen during the past five years at a tertiary care referral centre. Records were analysed for efficacy, toxicity and outcomes with EMACO regimen. Total of eight patients received EMACO during the study period. Median age at presentation was 25 years. All patients, except one gave a history of an antecedental molar pregnancy. The mean duration of development of GTN from the index pregnancy was 3.4 months. FIGO stage I, II and III were seen in one, three and four patients respectively. The average quantitative human chorionic gonadotrophin (hCG) prior to starting EMACO was 157,705 IU/L (6149-629,442 IU/L). The mean number of EMACO cycles for achieving normal hCG levels was 4 (2-6). All but one patient also received two additional cycles of consolidation chemotherapy. Grade 3/4 neutropenia was seen in seven patients. Hepatotoxicity was seen in one patient. At a median follow up of 36 months (18-50 months), all but one patient was alive, and four patients have successfully conceived, while three delivered healthy babies after receiving EMACO regimen. EMACO is a highly effective regimen with manageable toxicity, good patient compliance and fertility preservation. EMACO administration requires experienced multidisciplinary team approach which can help to adequately monitor response, manage toxicity, provide supportive care and detect early relapses.
Metrics
References
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531-9. DOI: https://doi.org/10.1016/j.ajog.2010.06.073
Hidayat YM, Darmadi AE, Rachmayati S, Kusumah WP, Djuwantono T, Pramatirta AY, et al. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients. Asian Pac J Cancer Prev. 2020;21(11):3325-29. DOI: https://doi.org/10.31557/APJCP.2020.21.11.3325
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-29. DOI: https://doi.org/10.1016/S0140-6736(10)60280-2
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(1):86-93. DOI: https://doi.org/10.1002/ijgo.13877
National Comprehensive Cancer Network. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gtn.pdf. 2025.
FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet. 2002;77(3):285-7. DOI: https://doi.org/10.1016/S0020-7292(02)00063-2
Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S; FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83(1):175-7. DOI: https://doi.org/10.1016/S0020-7292(03)90120-2
Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976;38(3):1373-85. DOI: https://doi.org/10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E
Brown J, Naumann RW, Seckl MJ, Schink J. 15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. Gynecol Oncol. 2017;144(1):200-7. DOI: https://doi.org/10.1016/j.ygyno.2016.08.330
Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. J Reprod Med. 2012;57(5-6):231-6.
Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;6:CD007102. DOI: https://doi.org/10.1002/14651858.CD007102.pub4
Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57(5-6):219-24.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018;143(2):79-85. DOI: https://doi.org/10.1002/ijgo.12615
Nzayisenga I, Segal R, Pritchett N, Xu MJ, Park PH, Mpanumusingo EV, et al. Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda. J Glob Oncol. 2016;2(6):365-74. DOI: https://doi.org/10.1200/JGO.2015.002568
Lu WG, Ye F, Shen YM, Fu YF, Chen HZ, Wan XY, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Int J Gynecol Cancer. 2008;18(2):357-62. DOI: https://doi.org/10.1111/j.1525-1438.2007.00999.x
Jain N, Pallavi VR, Shobha K, Rajshekhar K, Vanakudri T. 2022-RA-1187-ESGO Management and outcomes in high risk GTN-a regional cancer center experience. Int J Gynecol Cancer. 2022;32(2):A423. DOI: https://doi.org/10.1136/ijgc-2022-ESGO.908
Oranratanaphan S and Lertkhachonsuk R. Clinical Outcome and Survival of Post-molar GTN Versus Non-molar GTN Patients. Asian Pacific J Can Care. 2019;4(4):113-6. DOI: https://doi.org/10.31557/apjcc.2019.4.4.113-118
Hou YM, Li PP, Yu H, Feng F, He XY, Chen BH, et al. Clinical features and demographic characteristics of gestational trophoblastic neoplasia: Single center experience and the SEER database. Biomol Biomed. 2024;24(1):176-87. DOI: https://doi.org/10.17305/bb.2023.9092
Schmitt C, Doret M, Massardier J, Hajri T, Schott AM, Raudrant D, et al. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type. Gynecol Oncol. 2013;130(1): 86-9. DOI: https://doi.org/10.1016/j.ygyno.2013.03.010
Wang Q, Fu J, Hu L, Fang F, Xie L, Chen H, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017;9(9):CD007289. DOI: https://doi.org/10.1002/14651858.CD007289.pub3
Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, et al. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. J Reprod Med. 2010;55(7-8):279-84.
Taylor F, Grew T, Everard J, Ellis L, Winter MC, Tidy J, et al. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. Eur J Cancer. 2013;49(15):3184-90. DOI: https://doi.org/10.1016/j.ejca.2013.06.004
Alazzam M, Tidy J, Hancock BW, Osborne R and Lawrie TA. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012;7(7):10. DOI: https://doi.org/10.1002/14651858.CD007102.pub3
Lybol C, Thomas CM, Blanken EA, Sweep FC, Verheijen RH, Westermann AM, et al. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer. 2013;49(4):860-7. DOI: https://doi.org/10.1016/j.ejca.2012.09.015
Jareemit N, Therasakvichya S, Freitas F, Paiva G, Ramírez LAC, Berkowitz RS, et al. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study. Gynecol Oncol. 2023;170:114-22. DOI: https://doi.org/10.1016/j.ygyno.2022.12.020
Cyriac S, Rajendranath R, Sridevi V, Sagar TG. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy. J Reprod Med. 2011;56(5-6):219-23.
Turan T, Karacay O, Tulunay G, Boran N, Koc S, Bozok S, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2006;16(3):1432-8. DOI: https://doi.org/10.1111/j.1525-1438.2006.00606.x
Sharami SR, Saffarieh E. A review on management of gestational trophoblastic neoplasia. J Family Med Prim Care. 2020;9:1287-95. DOI: https://doi.org/10.4103/jfmpc.jfmpc_876_19
Gupta N, Takkar N. Fertility preservation in women undergoing treatment for malignancies: a narrative review. Int J Reprod Contracept Obstet Gynecol. 2024;13(3):776-83. DOI: https://doi.org/10.18203/2320-1770.ijrcog20240499
Chauhan A, Dave K, Desai A, Mankad M, Patel S, Dave P. High-risk gestational trophoblastic neoplasia at Gujarat Cancer and Research Institute: thirteen years of experience. J Reprod Med. 2010;55(7-8):333-40.
Wong JM, Liu D, Lurain JR. Reproductive outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia. J Reprod Med. 2014;59(5-6):204-8.
Gupta N, Pandey A, Dimri K, Prinja S. Epidemiological profile of Retinoblastoma in North India: Implications for Primary Care and Family Physicians. J Fam Med Prim Care. 2020;9:2843-8. DOI: https://doi.org/10.4103/jfmpc.jfmpc_265_20
Patel SM, Arora R, Tiwari R, Poddar P, Desai A, Mankad MH, et al. Management of “ultra‑high risk” gestational trophoblastic neoplasia at a tertiary center in India. Indian J Med Paediatr Oncol 2020; 41: 345-50. DOI: https://doi.org/10.4103/ijmpo.ijmpo_235_18
Gupta N, Dimri K, Garg SK, Pandey AK, Arora A. Outcomes with Methotrexate-Free Dyad Chemotherapy in Osteosarcoma Patients: Audit from a Resource-Limited Setting. Indian J Med Paediatr Oncol. 2024;46:191-9. DOI: https://doi.org/10.1055/s-0044-1795133
Babaier A, Jim B, Ghatage P. Management of EMA-CO resistant/refractory gestational trophoblastic neoplasia. Cancer Rep Rev. 2019;3:1-8. DOI: https://doi.org/10.15761/CRR.1000179
Sharayu M, Bijal P, Ava D, Shilpa P, Meeta M, Pariseema D. Role of Surgery in the Management of Gestational Trophoblastic Neoplasia. Indian J Gynecol Oncol. 2019;17(1):22. DOI: https://doi.org/10.1007/s40944-019-0263-8
Tejas SV, Pallavi VR, Shobha K, Rajshekhar SK. Role of Salvage Surgery in Gestational Trophoblastic Neoplasia: a Regional Cancer Centre Experience. Indian J Surg Oncol. 2022;13(4):702-6. DOI: https://doi.org/10.1007/s13193-022-01644-1
Gavanier D, Leport H, Massardier J, Abbas F, Schott AM, Hajri T, et al. Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study. Int J Clin Oncol. 2019;24(2):153-60. DOI: https://doi.org/10.1007/s10147-018-1337-9
Raudina F, Hidayat YM, Rachmayati S. Response to Chemotherapy in Patients with Gestational Trophoblastic Neoplasia in Dr. Hasan Sadikin General Hospital. AMJ. 2020;7(3):128-35. DOI: https://doi.org/10.15850/amj.v7n3.1894
Prinja S, Gupta N. Value based pricing for cancer drugs in India. Cancer Res Stat Treat. 2021;4:559-60. DOI: https://doi.org/10.4103/crst.crst_200_21
Gupta N, Chugh Y, Prinja S. Bridging the cancer care gap and inequities in radiation treatment in India: A narrative review. Cancer Res Stat Treat. 2023;6:554-61. DOI: https://doi.org/10.4103/crst.crst_295_23
Halder P, Dixit J, Gupta N, Mehra N, Singh A, Malhotra P, et al. Access to timely cancer treatment initiation in India: extent, determinants and trends. Lancet Reg Health Southeast Asia. 2024;32:100514. DOI: https://doi.org/10.1016/j.lansea.2024.100514
Carnelli L, Di Mattei V, Mazzetti M, Bernardi M, Di Pierro R, Bergamini A, et al. Illness Perception in Gestational Trophoblastic Disease Patients: How Mental Representations Affect Anxiety, Depression, and Infertility-Related Stress. Open J Med Psychol. 2017;6:1-15. DOI: https://doi.org/10.4236/ojmp.2017.61001
Gupta N, Pandey AK, Dimri K, Jyani G, Goyal A, Prinja S. Health related quality of life among breast cancer patients in India. Support Care Cancer. 2022;30(12):9983-90. DOI: https://doi.org/10.1007/s00520-022-07395-7
Downloads
Published
How to Cite
Issue
Section
